12Nov/13

Gilead Sciences, Inc. (GILD): Gilead Five-year Revenue Outlook, Part 1 – Seeking Alpha

Gilead Sciences, Inc. (GILD): Gilead Five-year Revenue Outlook, Part 1
Seeking Alpha
submitted a NDA to the FDA for marketing approval to support the use of Idelalisib, for the treatment of indolent non-Hodgkin’s lymphoma for patients with refractory iNHL (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy.

and more »

12Nov/13

Child Killer Asks to be Organ Donor; Wisconsin Court Weighs Collective … – Wall Street Journal (blog)

Child Killer Asks to be Organ Donor; Wisconsin Court Weighs Collective
Wall Street Journal (blog)
Boston bomber: Attorneys for accused Boston Marathon bomber Dzhokhar Tsarnaev are back in court Tuesday to argue against the restrictive terms of his confinement. Reuters. Out of practice: New York’s top court could soon consider whether an illegal 

and more »